SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the focal point, with traders watching guidance, subscriber engagement, advertising growth, and content strategy amid leadership changes and layoffs. Bearish concerns about competition, content quality, and slowing growth contrast with bullish hopes that low expectations and ad expansion could support a positive reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is drawing attention as traders position around the full Phase 3 melanoma cancer-vaccine data presentation at ESMO, following previously reported positive topline results. Bulls see the readout as validation of the oncology pipeline, while skeptics warn that expectations and valuation are elevated and debate whether the event could prompt profit-taking.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is drawing attention, with traders attributing the move to possible short covering and technical buying rather than a confirmed new company announcement. The broader debate centers on upcoming DM1 and FSHD siRNA data: Novartis/Aviditys DM1 trial failure raised concerns about whether target knockdown can translate into patient benefit, while some traders argue Sareptas distinct delivery approach and the loss of a competitor could be favorable.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are falling amid concern over plans to list its Monee financial-services arm and launch Sea Cloud, which traders worry could add spending and strategic uncertainty. The community is split between viewing a Monee separation as a potential value unlock and fearing it could weaken the remaining business, while some see the selloff as an overreaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings beat and a new buyback authorization, as traders focus on narrowed full-year profit guidance with an unchanged midpoint and weaker vehicle sales. Some view the drop as overdone given the stronger cash-flow outlook and buyback, while others see the outlook as too cautious to offset the earnings-day disappointment.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook drew attention as shares sold off despite strong demand, with traders frustrated by the reaction. The debate centers on whether higher costs, weaker cash generation and an insurance loss outweigh the stronger orders and guidance.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside new BRIUMVI data. Traders are hopeful azer-cel could add a growth opportunity beyond BRIUMVI, while recognizing the early readouts efficacy is uncertain; continued BRIUMVI sales growth is the more established part of the story.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers push to a fresh 52-week high is drawing attention, with traders celebrating a long-awaited recovery and debating whether the breakout can hold or will meet resistance. Some point to defensive-sector demand and pipeline progress, while others say the move needs a clearer company-specific catalyst.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention to the drugs potential and analyst optimism. Traders are debating whether the placebo-adjusted benefit is modest and whether agitation concerns and higher discontinuations could limit the upside, with some viewing the move as vulnerable to a fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a balance-sheet and strategic boost. Others question the deal because the divested unit contributes revenue, raising concerns about debt and the outlook for the remaining business; some traders are also taking profits after the surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy

Equity

Artiva announced a $300 million public offering to support the development of its autoimmune disease therapies, but at a 9% discount per share compared to Thursday’s closing price.

Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise

(RTTNews) - Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants...

Artiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Monday...

Artiva Biotherapeutics (NASDAQ:ARTV) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are covering the stock, Marketbeat.com reports. One...

Artiva Biotherapeutics (NASDAQ:ARTV) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Monday...

Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said...

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Artiva reported positive early clinical data for its AlloNK cell therapy in patients with difficult-to-treat rheumatoid arthritis and other autoimmune diseases.</li><li>The U.S. Food and Drug Administration has aligned with the biotech firm on a single Phase 3 registrational trial.</li><li>Artiva reported a loss of $0.95 per share, compared to estimates of a loss of $0.86 per share.</li></ul>Shares of Artiva Biotherapeutics (ARTV) pared early premarket gains on Friday, after a discounted $300 million public offering and a wider-than-expected first-quarter (Q1) loss weighed on sentiment even as the biotech firm announced promising clinical results for its rheumatoid arthritis and autoimmune disease therapy.On Friday, Artiva reported a net loss of $23.5 million, or $0.95 per share, wider than analysts’ expectations of a loss of $0.86 per share, according to Fiscal.ai data.<h2 class="st-heading-2">ARTV’s Phase 2 Trial Shows Significant Symptom Improvement</h2>Artiva reported positive early clinical data for its AlloNK cell therapy in patients with difficult-to-treat rheumatoid arthritis (RA) and other autoimmune diseases. In the ongoing Phase 2a trial, 71% of refractory RA patients with at least six months of follow-up achieved an ACR50 response, a key measure showing significant symptom improvement.The company said no patients relapsed or required additional treatments during follow-up. Artiva also highlighted favorable safety and tolerability results for the AlloNK plus Rituximab drug treatment regimen.No cases of cytokine release syndrome (CRS), neurotoxicity (ICANS), or treatment discontinuations were reported, supporting the potential for outpatient use in community rheumatology clinics.More than 70 autoimmune patients have been treated with AlloNK across over 40 active clinical sites globally. The U.S. Food and Drug Administration (FDA) has aligned with Artiva on a single Phase 3 registrational trial comparing AlloNK plus Rituximab against Rituximab alone in about patients. The company plans to begin the trial in the second half of 2026.<h2 class="st-heading-2">ARTV’s $300M Offering</h2>Separately, the biotech firm announced the pricing of an underwritten public offering that is expected to raise about $300 million in gross proceeds. The company is set to sell nearly 23.9 million shares of common stock at $11.52 per share, along with pre-funded warrants to purchase about 2.17 million additional shares for certain investors. This represents a 9% discount from the stock’s Thursday closing price.Artiva said all securities in the offering are being sold directly by the company to support the development of its autoimmune disease therapies.<h2 class="st-heading-2">What Does Retail Think Of ARTV?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ARTV">ARTV</a> on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, while message volumes were ‘high.’One user called the Phase 3 approval “solid news” and expected the stock to rally after breaking past $16.<stembedurl>https://stocktwits.com/The_Assassin/message/652705720</stembedurl>The stock has gained more than 190% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-price-rocket-lab-q1-earnings-analyst-price-targets/cZX2jVZReXw">RKLB Stock Is Back In Rally Mode After Q1 Earnings – And Retail Traders Want $100 Next</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$6.58
Prev Close	$5.89
Open	$6.05
Dividend Yield	0.00%
50-Day Moving Average	$9.21
Beta	1.49
Avg. Volume	481,000.87
PE Ratio	-1.78

52-Week High	$14.53
52-Week Low	$2.96
Market Capitalization	$287.96M
EPS (Annual)	-$3.43
Price to Book	0.83
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARTV Fundamentals